rs475688 — SLC22A12

Intronic regulatory variant in the URAT1 renal urate transporter gene; the T allele upregulates SLC22A12 expression, increasing urate reabsorption and raising serum uric acid, with TT individuals at substantially higher gout risk

See your personal result for SLC22A12

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

SLC22A12 rs475688 — When the Kidney Hoards Uric Acid

Every day, your kidneys filter roughly 7–8 grams of uric acid from your blood. Almost all of it — about 90% — is immediately reabsorbed back into circulation, with just 10% making it into the urine. The protein responsible for most of this reabsorption is URAT111 URAT1
Urate transporter 1 — an antiporter on the apical membrane of proximal tubule cells; it imports urate into the tubule cell in exchange for organic anions (lactate, nicotinate, pyrazinoate), effectively rescuing urate from the filtrate before it reaches the collecting duct, encoded by SLC22A12. The rs475688 variant sits deep in an intron of this gene, where it acts as an expression switch: the T allele turns URAT1 expression up, producing more transporter protein on the tubule surface and reabsorbing more urate with every liter of filtrate.

The Mechanism

Unlike missense variants that change the URAT1 protein's function, rs475688 changes how much URAT1 is made. A 2025 study in the Journal of Clinical Investigation established rs475688 as a kidney eQTL22 kidney eQTL
expression quantitative trait locus — a genetic variant that alters how strongly a nearby gene is expressed in a specific tissue, measurable by comparing mRNA levels across genotypes in that tissue for SLC22A12 in the renal proximal tubule. Each copy of the T allele adds a measurable increment to SLC22A12 mRNA levels, which translates directly to more URAT1 protein at the tubule surface, higher fractional urate reabsorption, and a raised serum urate setpoint.

The same study revealed an important gene-environment interaction: T carriers show a synergistically amplified urate response to hyperinsulinemia33 hyperinsulinemia
chronically elevated blood insulin levels, typically seen in insulin resistance, metabolic syndrome, and early type 2 diabetes; insulin independently stimulates URAT1 activity via AKT-mediated phosphorylation of URAT1-Thr408, an effect compounded when more URAT1 protein is available. This means high-carbohydrate diets and insulin resistance can interact multiplicatively with rs475688 to push urate levels well above what either factor would cause alone.

High fructose intake deserves separate mention: fructose metabolism consumes ATP rapidly (generating AMP → IMP → hypoxanthine → xanthine → urate), producing a urate surge that is then retained more efficiently in T allele carriers because URAT1 has a lower renal urate excretion efficiency.

The Evidence

The T allele's effect on urate was quantified at scale in 377,358 UK Biobank participants44 377,358 UK Biobank participants
Hosoyamachi S et al. Gene-environment interaction modifies the association between hyperinsulinemia and serum urate levels through SLC22A12. J Clin Invest, 2025: serum urate rose by 3.58 µmol/L per T allele copy (P = 4.54 × 10⁻⁸⁰), with CC individuals averaging 306.7 µmol/L, CT averaging 309.7 µmol/L, and TT averaging 313.3 µmol/L. This 6.6 µmol/L step from CC to TT is clinically meaningful at the tipping point near the urate supersaturation threshold55 supersaturation threshold
Urate becomes sparingly soluble in plasma at approximately 408 µmol/L (6.8 mg/dL) — above this concentration, monosodium urate crystals can nucleate and deposit in joints, tendons, and soft tissues, triggering gout of ~408 µmol/L (6.8 mg/dL).

A meta-analysis of 7 studies66 meta-analysis of 7 studies
Zou B et al. Associations between the SLC22A12 gene and gout susceptibility: a meta-analysis. Clin Rheumatol, 2018 (1,216 gout cases, 1,844 controls) found that having at least one risk allele compared to the low-risk homozygote was associated with OR = 2.03 (95% CI 1.49-2.76) for gout. A separate Japanese case-control study77 Japanese case-control study
Nakayama A et al. Additive composite ABCG2, SLC2A9 and SLC22A12 scores of high-risk alleles with alcohol use modulate gout risk. J Hum Genet, 2016 found that the SLC22A12 risk allele independently predicted gout with OR 1.95 per allele copy, and that risk alleles across ABCG2, SLC2A9, and SLC22A12 compounded in additive fashion — particularly in heavy drinkers, where alcohol metabolism drives both purine production and lactate-mediated URAT1 stimulation.

Population variation in rs475688 is striking: in European and African populations the T allele runs at ~26-32%, while in East Asian populations (Japanese, Korean, Vietnamese) T approaches 50% or higher — the population with the highest gout prevalence globally88 highest gout prevalence globally
Gout affects 3-4% of adults in many East Asian countries, compared to 2-3% in Western populations, with male-predominant hyperuricemia rates of 10-30% in Korea and Japan; this excess is multifactorial but URAT1 genetics likely contribute.

Practical Actions

For TT individuals, the urate setpoint is measurably higher and the kidney is working against any dietary effort to lower urate. The most effective strategy is reducing urate production (limit high-purine foods and fructose) while also reducing the competing organic anion substrates that URAT1 uses to cotransport urate (lactate from alcohol, nicotinate from certain supplements). If serum urate is persistently above 6.0 mg/dL despite dietary changes, uricosuric medications — which directly inhibit URAT1 — are the mechanistically appropriate drug class for this genotype.

For CT individuals, the same directional advice applies at lower urgency. Serum urate monitoring and preemptive dietary attention to fructose and purine load are appropriate.

Interactions

The rs475688 interaction with SLC2A9 (rs1079128, rs11942223) is additive: individuals who carry T alleles at both loci have URAT1 overexpression AND GLUT9 overexpression — two complementary reabsorption mechanisms both running hot. ABCG2 (rs2231142) is a urate efflux transporter on the intestinal epithelium; ABCG2 dysfunction and URAT1 overexpression combine to raise serum urate from both ends (reduced gut secretion and increased renal reabsorption).

The insulin-URAT1 pathway (via AKT phosphorylation of URAT1-Thr408) means that metabolic syndrome and insulin resistance are particularly hazardous for T allele carriers — managing blood sugar helps manage urate.

Nutrient Interactions

purines altered_metabolism
fructose altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

CC Low-Risk URAT1 Normal

Normal URAT1 expression — typical renal urate handling

The CC genotype produces typical SLC22A12 mRNA levels in the proximal tubule. With URAT1 abundance at baseline, the kidney reabsorbs urate at the standard rate (~90% of filtered load), and your serum urate setpoint is governed primarily by purine intake, kidney function, and competing genetic factors at other loci such as SLC2A9 and ABCG2.

In the UK Biobank analysis (n=377,358), CC individuals averaged 306.7 µmol/L serum urate — the lowest of the three genotypes. Gout risk is not elevated by this variant specifically, though other genetic and lifestyle factors still apply.

CT Elevated URAT1 Intermediate

One T allele — modestly elevated URAT1 expression and urate reabsorption

As a CT heterozygote, one of your SLC22A12 copies carries the T allele that upregulates gene expression in the renal proximal tubule. This intermediate dosage means URAT1 expression sits between the CC and TT states, resulting in a modest elevation in renal urate reabsorption efficiency. The eQTL effect size (effect per T allele: +3.58 µmol/L, P=4.54×10⁻⁸⁰) is highly consistent across large cohorts, confirming the additive nature of this variant.

The interaction with insulin is relevant: if you develop hyperinsulinemia (common in overweight, sedentary, or high-carbohydrate dietary conditions), insulin stimulates URAT1-Thr408 phosphorylation via AKT, increasing URAT1 transport activity beyond the baseline eQTL elevation. T allele carriers show a synergistically amplified response to this mechanism.

Meta-analysis gout odds ratios are intermediate between CC and TT — having one T allele confers meaningfully elevated risk compared to CC, particularly in the context of other risk factors.

TT High URAT1 High Risk

Two T alleles — substantially elevated URAT1 expression and high gout risk

With two T alleles, both SLC22A12 copies express the upregulated eQTL effect. URAT1 protein abundance on the proximal tubule surface is at its highest genetically determined level, and renal urate retention is maximally elevated by this variant. The additive eQTL effect is linear: TT individuals show approximately twice the expression increment of CT individuals, and the serum urate step (CC → CT → TT) is consistent with an additive model.

The Hosoyamachi et al. 2025 JCI study demonstrated that T allele carriers have a synergistically amplified urate response to hyperinsulinemia: insulin stimulates URAT1 activity via AKT-mediated Thr408 phosphorylation, and this signal is amplified when more URAT1 is available. This means TT individuals with metabolic syndrome, insulin resistance, or high-carbohydrate diets face compounded risk beyond the eQTL elevation alone.

The meta-analysis of gout case-control studies (Zou et al. 2018, n=3,060) found CC+CT vs. TT OR=2.03 (95% CI 1.49-2.76), and a separate Japanese study found an OR of ~1.95 per risk allele in an additive model with alcohol use further compounding risk. For TT individuals, gout prevention requires active management: serum urate monitoring, dietary optimization, and awareness that uricosuric drugs (which block URAT1 directly) are the most mechanistically targeted pharmacological option if diet alone is insufficient.